Epitomee Medical
Caesarea, Israel· Est.
A platform for pH‑triggered, biodegradable oral capsules that provide targeted GI therapy for chronic disease.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A platform for pH‑triggered, biodegradable oral capsules that provide targeted GI therapy for chronic disease.
ObesityMetabolic DisordersGastroenterology
Technology Platform
Self‑expanding hydrogel scaffold folded into a swallowable capsule that deploys at pH‑specific GI locations, providing transient, biodegradable therapeutic activity.
Opportunities
Large, unmet need for oral delivery of biologics and weight‑management therapies; potential licensing deals with pharma to repurpose pipeline assets for the GI platform.
Risk Factors
Regulatory approval for novel ingestible devices; clinical validation of efficacy and safety; competition from established oral drug‑delivery technologies.
Competitive Landscape
Competes with other GI‑targeted delivery systems (e.g., Medtronic’s GI pumps, Intestine‑specific capsules) but differentiates through a fully biodegradable, pH‑triggered hydrogel scaffold that can be customized for multiple indications.